CIPROCIN

For The Medical Profession Only

CIPROCIN

Film-Coated Tablets - Vials (IV) Broad - Spectrum Fluoroquinolone Antibacterial

Indications:

 -Treatment of infections due to susceptible micro-organisms:

 -Urinary tract infections.

 -Acute sinusitis, and malignant otitis externa.

-Lower respiratory tract infections.

 -Exacerbations of cystic fibrosis.

 -Bone and joint infections.

 -Skin and soft tissue infections.

 -Gastrointestinal tract infections including biliary tract infections, infectious diarrhea, typhoid and paratyphoid fevers.

 -Genital tract infections: prostatitis, gonorrhea and chancroid.

-Septicemia and peritonitis.

-Surgical infection prophylaxis.

 -Meningococcal meningitis prophylaxis.

 -Infections in immunocompromised patients (neutropenia).

 -Inhalation anthrax.

 Dosage and Administration:

Oral Route Clprocinn can be taken without regard to meals. CiprocIn8 Tablets should be given every 12 hours.

Properties:

 CiprocIn0 is one of the most potent of the fluoroquinolone antibacterial group. It is bactericidal acting by inhibition of the A subunit of DNA gyrase enzyme essential for bacterial DNA reproduction. Clprocin® has a broad spectrum of activity against most Gram-negative bacteria and many Gram-positive bacteria including Enterobacteriaceae. including E. coli. Proteus, Klebsiella, Salmonella, Shigella. Serratia, Citrobacter. Enterobacter, Providentia, Yersinia; Pseudomonas aeruginosa: Moraxella catarrhalis and Haemophilus inlluenzae (including beta-lactamase producing strains). Haemophilus parainfluenzae and ducreyi, Neisseria gnonorrhoeae (including beta-lactamase producing strains), Neisseria meningitidis. Campylobacter app., and Vibrio spp.; Staphylococci (including penicillinase-producing and penicillinase-nonproducing strains and some methicillin-resistant strains). Streptococci (including pyogenes, faecalis and

pneumoniae). Clprocin® has some activity against mycobacteria, and mycoplasmas.

Pharmacokinetics:

 Ciprofloxacin is rapidly and well absorbed from the gastrointestinal tract. Oral bioavailability is about 70% and a peak plasma concentration is achieved 1 - 2 hours after a dose of 500 mg by mouth. Absorption may be delayed by the presence of food but is not substantially affected overall. Plasma half-life is about 3.5 - 4.5 hours. Protein binding ranges from 20 - 40%. Ills widely distributed in the body and tissue penetration is generally good. High concentrations are achieved in bile. Ciprofloxacin is eliminated primarily by urinary excretion, but non-renal clearance may account for about a third of elimination and includes hepatic metabolism, biliary excretion and possible transluminal secretion across the intestinal mucosa. About 40 - 50% of the oral dose is excreted unchanged in urine and about 15% as metabolites which have antimicrobial activity, but are less active than unchanged ciprofloxacin. Up to 70% of the parenteral dose may be excreted unchanged and within 24 hours and 10% as metabolites. Fecal excretion over 5 days has accounted for 20- 30% of an oral dose and 15% of an intravenous dose.